A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14685 ↗At a glance
Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, 2024. Written by Richard B Lipton and 5 co-authors. Institution: Department of Neurology Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA. Major MEDLINE topics: Dihydroergotamine, Mesylates, Migraine Disorders. Cited 13 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Satsuma Pharmaceuticals, Inc.
Abstract (original language)
Objective
To compare the safety and pharmacokinetics (PK) of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), liquid nasal spray (LNS) DHE mesylate, and intramuscular (IM) DHE mesylate injection in healthy participants.
Background
DHE is an effective acute migraine treatment; however, self‐administration difficulties have prevented its broader role in the management of migraine.
Methods
This randomized, active‐controlled, five‐period crossover study was conducted over 5 weeks separated by 1‐week washout periods. Three STS101 dosage strengths (5.2, 7.0, 8.6 mg), and one dose each of LNS DHE 2.0 mg, and IM DHE 1.0 mg, were administered to 36 healthy participants. Liquid chromatography, tandem mass spectrometry was used to determine DHE (including its 8′OH‐DHE metabolite) plasma levels and to calculate PK parameters ( C max , T max , AUC 0‐2h , AUC 0‐last , AUC 0‐inf , and t 1/2 ). Safety was evaluated by monitoring adverse events (AEs), vital signs, electrocardiograms, nasal examinations, and laboratory parameters.
Results
Thirty‐six participants (mean age 36 years; 19% Hispanic Black and 81% Hispanic White) were enrolled. DHE plasma concentrations rose rapidly after STS101 5.2, 7.0, and 8.6 mg and IM DHE injection, with mean concentrations greater than 2000 pg/mL for all STS101 dose strengths at 20 min. All STS101 dose strengths showed approximately 3‐fold higher C max , AUC 0‐2h , and AUC 0‐inf , than the LNS DHE. The mean AUC 0‐inf of STS101 7.0 and 8.6 mg were comparable to IM DHE (12,600 and 13,200 vs. 13,400 h × pg/mL). All STS101 dose strengths showed substantially lower variability (CV%) compared to LNS DHE for C max (35%–41% vs. 87%), and AUC 0‐inf (37%–46% vs. 65%). STS101 was well tolerated, and all treatment‐emergent AEs were mild and transient.
Conclusion
STS101 showed rapid absorption and was well tolerated with mild and transient treatment‐emergent AEs. Achieving effective DHE plasma concentrations within 10 min, STS101 displayed a favorable PK profile relative to the LNS with higher C max , AUC 0‐2h , and AUC 0inf , and with greater response consistency. The AUC 0‐inf was comparable to IM DHE.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.
- Satsuma Pharmaceuticals Inc., Durham, North Carolina, USA.
- Quotient Sciences, Miami, Florida, USA.
- Allucent, Gary, North Carolina, USA.
ORCID profiles: Richard B Lipton
Funding
- Satsuma Pharmaceuticals, Inc
Cite
APA
Lipton, R. B., Albrecht, D., Bermudez, M., Hu, J., Hussey, E., & Levy, J. (2024). A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14685
Vancouver
Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14685
BibTeX
@article{Lipton2024,
author = {Lipton, Richard B and Albrecht, Detlef and Bermudez, Maria and Hu, Jerry and Hussey, Elizabeth and Levy, Jeff},
title = {A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14685}
}
EUVIMED